Hunan Jingfeng Pharmaceutical Co

Hunan Jingfeng Pharmaceutical Co EV/EBIT

The EV/EBIT (Enterprise Value to EBIT) of Hunan Jingfeng Pharmaceutical Co (000908.SZ) as of Oct 19, 2026 is -210.12. In the previous year, EV/EBIT (Enterprise Value to EBIT) was 28.74 — a change of -831.09% (lower).

EV/EBIT

-210.12

YoY

-831.09%

Last updated:

EV/EBIT (Enterprise Value to EBIT) of Hunan Jingfeng Pharmaceutical Co is 2025 -210.12 . EV/EBIT (Enterprise Value to EBIT) of Hunan Jingfeng Pharmaceutical Co was 2024 28.74 . It decreases by -831.09% lower compared to the previous year.

The Hunan Jingfeng Pharmaceutical Co EV/EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/EBIT
Date
EV/EBIT
Jan 1, 2018
22.98 CNY
Jan 1, 2019
-6.45 CNY
Jan 1, 2020
-5.21 CNY
Jan 1, 2021
-43.12 CNY
Jan 1, 2022
-85.77 CNY
Jan 1, 2023
-33.89 CNY
Jan 1, 2024
28.74 CNY
Jan 1, 2025
-210.12 CNY
The Hunan Jingfeng Pharmaceutical Co EV/EBIT history
YEAREV/EBITYoY
-210.12-831.09%
28.74-184.81%
-33.89-60.49%
-85.77+98.91%
-43.12+726.83%
-5.21-19.15%
-6.45-128.06%
22.98+1.24%
22.70+70.74%
13.30-5.66%
14.09-29.38%
19.96+79.47%
11.12-40.09%
18.56-178.51%
-23.64-75.33%
-95.81+708.52%
-11.85-57.45%
-27.85-99.29%
-3,901.27—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Hunan Jingfeng Pharmaceutical Co Valuation

Details

Historical Valuation Multiples

ⓘ

Price-to-Earnings Ratio (P/E)

The P/E ratio divides Hunan Jingfeng Pharmaceutical Co's share price by its earnings per share. It tells you how many years of current earnings you are "paying for" when you buy the stock. A P/E of 20 means you pay $20 for every $1 of annual earnings. The S&P 500 historically trades at an average P/E of roughly 15–17. A P/E significantly above that may signal high growth expectations; one below may indicate undervaluation — or declining business quality.

Price-to-Sales Ratio (P/S)

The P/S ratio divides market capitalization by total revenue. Unlike the P/E ratio, it works even for companies that are not yet profitable, making it essential for evaluating high-growth firms. A P/S below 1.0 may indicate undervaluation, while ratios above 10 are typically reserved for fast-growing tech or SaaS companies with high expected future margins.

Price-to-EBIT Ratio

This ratio relates Hunan Jingfeng Pharmaceutical Co's market price to its operating earnings, excluding the effects of debt structure and tax jurisdiction. It is particularly useful for comparing companies across different countries or with different levels of leverage, because it focuses purely on operational profitability. Lower values suggest cheaper operational earnings.

How to Use This Chart

This chart plots Hunan Jingfeng Pharmaceutical Co's valuation multiples over time. Compare the current P/E, P/S, and P/EBIT to their own historical averages — if the current ratio is well below the multi-year average, the stock may be relatively cheap compared to its own track record. Combine this with industry comparisons: a P/E that looks high in absolute terms may be justified if Hunan Jingfeng Pharmaceutical Co grows earnings faster than its peers.

Hunan Jingfeng Pharmaceutical Co Stock analysis

What does Hunan Jingfeng Pharmaceutical Co do? Hunan Jingfeng Pharmaceutical Co Ltd, based in Shanghai, China, operates in the Health Care sector, specializing in pharmaceuticals. The company develops, manufactures, and sells chemical and biological drugs, including cardio and cerebrovascular, antihypertensive, orthopedic, anti-tumor, endocrine, digestive, antiviral, and anti-infective products. It employs 645 people and distributes its products domestically within China. The firm also engages in import/export trading, business consulting, and medical technology advisory services. Hunan Jingfeng Pharmaceutical Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Hunan Jingfeng Pharmaceutical Co stock

EV/EBIT (Enterprise Value to EBIT) of Hunan Jingfeng Pharmaceutical Co is -210.12 in 2025.

EV/EBIT (Enterprise Value to EBIT) of Hunan Jingfeng Pharmaceutical Co changed from 28.74 to -210.12, representing a -831.09% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EV/EBIT (Enterprise Value to EBIT) Hunan Jingfeng Pharmaceutical Co since 2006 – with annual values, charts, and detailed analysis.

The EV/EBIT ratio measures a company's enterprise value relative to its operating earnings. It accounts for debt, making it useful for comparing companies with different capital structures.

EV/EBIT = Enterprise Value / Earnings Before Interest and Taxes

To evaluate EV/EBIT (Enterprise Value to EBIT)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/EBIT (Enterprise Value to EBIT).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/EBIT (Enterprise Value to EBIT)'s Hunan Jingfeng Pharmaceutical Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Valuation — Hunan Jingfeng Pharmaceutical Co

P/EP/SEV/EBITP/BP/CFP/FCFPEGEV/RevenueEV/EBITDAEV/FCFEarnings YieldFCF YieldMarket capitalizationEnterprise ValueForward P/EP/TBVShareholder YieldBuyback YieldDiv.-Adj. PEGEV/OCF

All Key Metrics — Hunan Jingfeng Pharmaceutical Co